Breast Cancer Research and Treatment

, Volume 20, Issue 1, pp 11–17

Platelet-derived growth factor (PDGF) in plasma of breast cancer patients: Correlation with stage and rate of progression

  • S. Ariad
  • L. Seymour
  • W. R. Bezwoda
Report

DOI: 10.1007/BF01833352

Cite this article as:
Ariad, S., Seymour, L. & Bezwoda, W.R. Breast Cancer Res Tr (1991) 20: 11. doi:10.1007/BF01833352

Abstract

Plasma levels of platelet-derived growth factor (PDGF) were measured in 58 female patients with breast cancer and in 9 normal female control subjects by means of a specific radioimmunoassay. Levels in normal control subjects were all below the lower limits of detection by the assay (1.56 fmol/100 µl plasma). Two of 17 (12%) patients with stage 2 breast cancer had detectable plasma levels. Among patients with Stage 4 breast cancer 13/41 (32%) had significantly elevated levels (> 2 times the lower limit of sensitivity of the assay). Patients with elevated PDGF levels had a significantly greater degree of metastatic involvement and significantly shorter survival. Apart from being a marker of aggressive high bulk breast cancer, PDGF may be involved in the acceleration of growth of some metastatic breast tumors.

Key words

platelet-derived growth factorplasma concentrationsimmunoassaybreast cancerprognosistumor progression

Copyright information

© Kluwer Academic Publishers 1991

Authors and Affiliations

  • S. Ariad
    • 1
  • L. Seymour
    • 1
  • W. R. Bezwoda
    • 1
  1. 1.Department of Medicine, Hematology/Oncology UnitUniversity of the Witwatersrand Medical School and Johannesburg HospitalJohannesburgSouth Africa